<DOC>
	<DOCNO>NCT00002865</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness high-intensity , brief-duration chemotherapy treat patient relapsed refractory acute lymphocytic leukemia .</brief_summary>
	<brief_title>High-Intensity , Brief-Duration Chemotherapy Treating Patients With Relapsed Refractory Acute Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine complete response rate high-intensity , brief-duration chemotherapy cyclophosphamide , methotrexate , vincristine , doxorubicin , dexamethasone follow ifosfamide , methotrexate , vincristine , cytarabine , etoposide , dexamethasone patient relapse refractory acute lymphocytic leukemia ( ALL ) . II . Determine toxic effect regimens patient . OUTLINE : All patient receive six alternate course ( every 3-4 week ) two chemotherapy regimen : cyclophosphamide , oral dexamethasone , methotrexate leucovorin rescue , vincristine , doxorubicin 5 day ; ifosfamide/mesna , oral dexamethasone , methotrexate leucovorin rescue , vincristine , cytarabine , etoposide 5 day . G-CSF give follow course recovery neutrophil count . All patient receive triple intrathecal chemotherapy day 1 . Patients CNS disease receive intrathecal therapy twice weekly CSF clear , weekly 4 week , monthly 1 year ; receive prior CNS irradiation also receive whole-brain radiotherapy . Patients follow monthly 6 month , every 3 month 18 month , every 6 month 2 year , annually . PROJECTED ACCRUAL : A total 37 evaluable patient accrue least 4 first 17 patient respond .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm acute lymphocytic leukemia relapse refractory induction therapy 1 2 prior induction allow , refractory 1 regimen CNS involvement allow PATIENT CHARACTERISTICS : Age : 18 Performance status : 03 Hematopoietic : Not specify Hepatic : Bilirubin great 1.5 time normal ( unless directly attributable leukemia ) Renal : Creatinine great 1.5 time normal ( unless directly attributable leukemia ) Cardiovascular : No uncontrolled severe cardiovascular disease include : Myocardial infarction within 6 month Congestive heart failure Other : No uncontrolled duodenal ulcer No uncontrolled infection No second malignancy within 5 year except curatively treat : In situ cervical cancer Basal cell skin cancer No serious medical illness would limit survival 2 year No psychiatric illness would prevent informed consent compliance No pregnant nursing woman Adequate contraception require fertile patient PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
</DOC>